experimental therapeutics center
AUM Biosciences Licenses Cancer Drug From A*STAR
The drug, ETC-206, was shown to be well tolerated in human trials and specifically targets cancer cells while leaving normal cells unharmed.
7 Must-Read Stories In July 2015
Singaporean stories proved popular in July, making up five of the top seven most read articles.
Made-In-Singapore Cancer Drug Advances To Clinical Trials
ETC-159, a Wnt-targeting anti-cancer drug indicated for colorectal, ovarian and pancreatic cancers, has entered a Phase I clinical trial.
Visterra & A*STAR To Bring Dengue Antibody To Clinical Trials
A*STAR's D3 has joined Visterra to bring the dengue monoclonal antibody VIS513 to proof-of-concept clinical trials.
A*STAR, AstraZeneca To Develop Gram-Negative Antibacterials
A*STAR has signed an agreement with biopharmaceutical company AstraZeneca to develop new drugs to treat gram-negative bacterial infections.
H1N1 Influenza Vaccine From A*STAR & Cytos Enters Phase I Trials
Singapore's A*STAR and Switzerland's Cytos Biotechnology AG today announced the initiation of Phase I trials for their H1N1 influenza vaccine candidate.
Dr. Alex Matter Awarded 2013 Szent-Györgyi Prize For Progress In Cancer Research
Dr. Alex Matter, father of targeted cancer therapies, will receive the 8th Szent-Györgyi Prize for Progress in Cancer Research this Friday in Washington, DC.
